Abstract:Background Platelets play a critical role in the formation of thrombosis and embolism, and high-sensitivity C-reactive protein (HS-CRP) is an important indicator of inflammation, which contribute to the development of ischemic stroke development. This study aimed to examine whether the relationship between baseline platelet count and adverse clinical outcomes is modulated by HS-CRP in patients with ischemic stroke. Methods A total of 3267 patients with ischemic stroke were included in the analysis. The primary outcome was a combination of death and major disability (modified Rankin Scale [mRS] score ≥3) at 1 year after ischemic stroke. Secondary outcomes included major disability, death, vascular events, composite outcome of vascular events or death, and an ordered 7-level categorical score of the mRS at 1 year. Multivariate logistic regression and Cox proportional hazards regression models were used to assess the association between the baseline platelet count and clinical outcomes stratified by HS-CRP levels when appropriate, odds ratio (OR) or hazard ratio (HR) and 95% confidence interval (CI) were calculated for the highest quartiles of platelet counts compared with the lowest quartile. Results The elevated platelet count was associated with the primary outcome (OR, 3.14;95% CI, 1.77-5.58), major disability (OR, 2.07;95%CI, 1.15-3.71), death (HR, 2.75;95%CI, 1.31-5.79), composite outcome of vascular events or death (HR, 2.57;95%CI, 1.38-4.87), and the ordered 7-level categorical score of the mRS at 1 year (OR, 2.01 [95%CI, 1.33-3.04]) among patients with high HS-CRP levels (all P trend <0.05). However, platelet count was not associated with the primary outcome (OR, 1.13; 95%CI, 0.75-1.71), major disability (OR, 1.34; 95%CI, 0.87-2.08), death (HR, 0.48; 95%CI, 0.19-1.24), composite outcome of vascular events or death (HR, 0.79; 95%CI, 0.45-1.37), and the ordered 7-level categorical score of the mRS at 1 year (OR, 1.17; 95%CI, 0.91-1.49) (all P trend >0.05) in those with low HS-CRP levels. There was an interaction effect of platelet count and HS-CRP on the primary outcome, death, composite outcome of vascular events or death, and the ordered 7-level categorical score of the mRS at 1 year after ischemic stroke (all P interaction <0.05). Conclusions An elevated platelet count was associated with adverse clinical outcomes in ischemic stroke patients with high HS-CRP levels but not in those with low HS-CRP levels, the HS-CRP level had a modifying effect on the association between platelet count and clinical outcomes in patients with ischemic stroke, suggesting that strategies for anti-inflammatory and antiplatelet therapy should be developed according to the results of both platelet and HS-CRP testing. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported by the National Natural Science Foundation of China (grant: 82020108028). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The clinical trial was approved by the Ethics Committee at Soochow University in China and Institutional Review Board at Tulane University in the United States, as well as ethics committees at the 26 participating hospitals. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data included in this study are available upon request by contact with the corresponding author. * CATIS : China Antihypertensive Trial in Acute Ischemic Stroke HS-CRP : high-sensitivity C-reactive protein BP : blood pressure NIHSS : National Institutes of Health Stroke Scale mRS score : modified Rankin Scale (ALLHAT) : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial OR : odds ratio HR : hazard ratio CI : confidence intervals BMI : body mass index SBP : systolic blood pressure DBP : diastolic blood pressure TG : triglycerides TC : total cholesterol LDL-C : low density lipoprotein cholesterol HDL-C : high density lipoprotein cholesterol TIA : transient ischemic attack

HS‐CRP Modifies the Prognostic Value of Platelet Count for Clinical Outcomes after Ischemic Stroke

High-sensitivity C-reactive protein modifies the prognostic value of platelet count for clinical outcomes after ischemic stroke

Baseline Platelet Count and Clinical Outcome in Acute Coronary Syndrome

Elevated C-Reactive Protein and Depressed High-Density Lipoprotein Cholesterol are Associated with Poor Function Outcome after Ischemic Stroke.

High-sensitivity C-reactive Protein As a Better Predictor of Post-Thrombolytic Functional Outcome in Patients with Previous Antiplatelet Therapy

Platelet Count Predicts Adverse Clinical Outcomes After Ischemic Stroke or TIA: Subgroup Analysis of CNSR II

Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke

Prognostic Value of C-Reactive Protein and Homocysteine in Large-Artery Atherosclerotic Stroke: a Prospective Observational Study

Platelet counts affect the prognostic value of homocysteine in acute ischemic stroke patients.

Association of Uric Acid, High-Sensitivity C-Reactive Protein, and 90-Day Risk of Poor Function Outcome in Patients with Ischemic Stroke or Transient Ischemic Attacks

High-sensitive C-reactive Protein and Stroke Outcomes in Patients with and Without Atrial Fibrillation

High On-Treatment Platelet Reactivity As Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents.

Relationship Between C - Reactive Protein and Stroke: A Large Prospective Community Based Study

Predictive role of pre-thrombolytic hs-CRP on the safety and efficacy of intravenous thrombolysis in acute ischemic stroke

Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients after Intravenous Thrombolysis

High On‐treatment Platelet Reactivity is Associated with Poor Outcomes after Ischemic Stroke: A Meta‐analysis

Association between high-sensitivity C-reactive protein, functional disability, and stroke recurrence in patients with acute ischaemic stroke: A mediation analysis

Can high-sensitivity C reactive protein (hsCRP) be used as a prognostic marker of functional disability after acute ischaemic stroke? A cross-sectional study at a tertiary care centre in Eastern India

Clinical study on the correlation between high sensitivity C-reactive protein and risk factors in cerebral vessal disease

Prognostic influence of C-reactive protein levels on acute ischemic stroke: a systematic review

Stroke Prognosis: the Impact of Combined Thrombotic, Lipid, and Inflammatory Markers